Featured Jobs
|
The Pension Source
|
|
Distributions Processor - Qualified Retirement Plans Anchor 3(16) Fiduciary Solutions, LLC
|
|
DWC ERISA Consultants LLC
|
|
Nova 401(k) Associates
|
|
BPAS
|
|
EPIC RPS
|
|
BPAS
|
|
Merkley Retirement Consultants
|
|
Compensation Strategies Group, Ltd.
|
|
Defined Benefit Specialist II or III Nova 401(k) Associates
|
|
Retirement Combo Plan Administrator Heritage Pension Advisors, Inc.
|
|
July Business Services
|
Free Newsletters
“BenefitsLink continues to be the most valuable resource we have at the firm.”
-- An attorney subscriber
|
|
|
GAO Report: Brand-Name Prescription Drug Pricing -- Lack of Therapeutically Equivalent Drugs and Limited Competition May Contribute to Extraordinary Price Increases
U.S. Government Accountability Office [GAO] 
Jan. 11, 2010
40 pages. "GAO was asked to examine extraordinary price increases for brand-name prescription drugs. Specifically, GAO examined the: [1] frequency of extraordinary price increases for brand-name prescription drugs from 2000 to 2008, [2] characteristics of the brand-name prescription drugs that had extraordinary price increases, and [3] factors that contributed to the extraordinary price increases experienced by these brand-name prescription drugs." [GAO-10-201, published Dec. 22, 2009, released Jan. 11, 2010]
|
| Please click here to report this link if it is broken (for example, if you see a "404 File Not Found" error message after you click on the linked news item's title). |
| An important word about authorship: BenefitsLink® created this link to the news item, but we are not the news item's author (unless expressly shown above). |